Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1606 to 1620 of 2028 results for nice guidelines

  1. Partial seizures in children and young people with epilepsy: zonisamide as adjunctive therapy (ESNM37)

    This evidence summary has been updated and replaced by NICE guideline NG217.

  2. Chronic obstructive pulmonary disease: aclidinium bromide (ESNM8)

    This evidence summary has been updated and replaced by NICE guideline 115.

  3. Chronic obstructive pulmonary disease: glycopyrronium bromide (ESNM9)

    This evidence summary has been updated and replaced by NICE guideline 115.

  4. Significant haemorrhage following trauma: tranexamic acid (ESUOM1)

    This evidence summary has been updated and replaced by NICE guideline NG39.

  5. Management of aggression, agitation and behavioural disturbances in dementia: carbamazepine (ESUOM40)

    This evidence summary has been updated and replaced by NICE guideline NG97.

  6. Attention deficit hyperactivity disorder in children and young people: clonidine (ESUOM8)

    This evidence summary has been updated and replaced by NICE guideline NG87.

  7. Early breast cancer (preventing recurrence and improving survival): adjuvant bisphosphonates (ES15)

    This evidence summary has been updated and replaced by NICE guideline NG101.

  8. Chronic obstructive pulmonary disease: beclometasone, formoterol and glycopyrronium (Trimbow) (ES17)

    This evidence summary has been updated and replaced by NICE guideline 115.

  9. Partial-onset seizures in epilepsy: zonisamide as monotherapy (ESNM17)

    This evidence summary has been updated and replaced by NICE guideline NG217.

  10. Attention deficit hyperactivity disorder in children and young people: lisdexamfetamine dimesylate (ESNM19)

    This evidence summary has been updated and replaced by NICE guideline NG87.

  11. Type 2 diabetes: alogliptin (ESNM20)

    This evidence summary has been updated and replaced by NICE guideline NG28.

  12. Chronic obstructive pulmonary disease: fluticasone furoate plus vilanterol (ESNM21)

    This evidence summary has been updated and replaced by NICE guideline 115.

  13. Asthma: beclometasone/formoterol (Fostair) for maintenance and reliever treatment (ESNM22)

    This evidence summary has been updated and replaced by NICE guideline NG80.

  14. Type 2 diabetes: lixisenatide (ESNM26)

    This evidence summary has been updated and replaced by NICE guideline NG28.

  15. Clopidogrel and modified-release dipyridamole in the prevention of occlusive vascular events (TA90)

    This guideline has been updated and replaced by NICE technology appraisal 210.